Generalized prurigo nodularis is a severe and widespread morphologic manifestation of chronic pruritus.1 This condition is challenging to treat and results in a high burden of disease.1 We examined the effectiveness of the interleukin (IL) 4 receptor α inhibitor dupilumab as a novel treatment option for generalized prurigo nodularis.
Beck KM, Yang EJ, Sekhon S, Bhutani T, Liao W. Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol. 2019;155(1):118–120. doi:10.1001/jamadermatol.2018.3912
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: